Quaker BioVentures
60
27M
37
2.73
13
0.38
19
- Stages of investment
- Areas of investment
Summary
Quaker BioVentures is the famous VC, which was founded in 2002. The main department of described VC is located in the Philadelphia. The venture was found in North America in United States.
The usual cause for the fund is to invest in rounds with 5-6 partakers. Despite the Quaker BioVentures, startups are often financed by Domain Associates, Investor Growth Capital Limited, Three Arch Partners. The meaningful sponsors for the fund in investment in the same round are Johnson & Johnson Development Corporation, Intersouth Partners, Investor Growth Capital Limited. In the next rounds fund is usually obtained by Johnson & Johnson Development Corporation, Investor Growth Capital Limited, Domain Associates.
Besides them, we counted 13 critical employees of this fund in our database.
For fund there is a match between the location of its establishment and the land of its numerous investments - United States. The fund has exact preference in a number of founders of portfolio startups. Among the various public portfolio startups of the fund, we may underline Celator Pharmaceuticals, Rapid Micro Biosystems, TetraLogic Pharmaceuticals Besides, a startup needs to be aged 6-10 years to get the investment from the fund. Among the most successful fund investment fields, there are Health Care, Health Diagnostics.
The higher amount of exits for fund were in 2017. The high activity for fund was in 2007. Despite it in 2019 the fund had an activity. Speaking about the real fund results, this VC is 8 percentage points more often commits exit comparing to other organizations. This Quaker BioVentures works on 1 percentage points more the average amount of lead investments comparing to the other organizations. The usual things for fund are deals in the range of 10 - 50 millions dollars. The fund is constantly included in 2-6 investment rounds annually.
Investments analytics
Analytics
- Total investments
- 60
- Lead investments
- 13
- Exits
- 19
- Rounds per year
- 2.73
- Follow on index
- 0.38
- Investments by industry
- Biotechnology (52)
- Health Care (51)
- Pharmaceutical (24)
- Medical (23)
- Therapeutics (22) Show 23 more
- Investments by region
-
- United States (60)
- Peak activity year
- 2007
- Number of Unicorns
- 1
- Number of Decacorns
- 1
- Number of Minotaurs
- 1
Discover reliable insights
Leverage validated data, identify key contacts and secure funding opportunities for your business.Quantitative data
- Avg. startup age at the time of investment
- 19
- Avg. valuation at time of investment
- 58M
- Group Appearance index
- 1.00
- Avg. company exit year
- 11
- Avg. multiplicator
- 1.03
- Strategy success index
- 0.70
Need more data?
Get access to full data about investors, including their team, contact information, and historic data.
Latest deals
Company name | Deal date | Industry | Deal stage | Deal size | Location |
---|---|---|---|---|---|
CloudApp | 29 May 2019 | Mobile, SaaS, Collaboration, Productivity Tools, Enterprise Software, Business Intelligence, Developer Tools, Video, Photo Sharing, File Sharing, Desktop Apps, Video Editing | Seed | 4M | United States, California, San Francisco |
Exo | 03 Mar 2017 | Health Care, Medical Device, Medical | Seed | United States, California, Redwood City | |
Precision Therapeutics | 22 Feb 2006 | Health Care, Personal Health, Pharmaceutical, Clinical Trials | Early Stage Venture | 20M | United States, Pennsylvania, Pittsburgh |
TearScience | 06 May 2010 | Biotechnology, Health Care, Medical Device, Medical, Clinical Trials | Late Stage Venture | 44M | United States, North Carolina |
Similar funds
By same location
By same geo focus
By doing lead investments
At Unicorn Nest, we combine cutting-edge technology with human expertise to build one of the most reliable venture capital databases in the market. Our process begins with automated AI-enhanced data collection, leveraging the full potential of Large Language Models (LLMs).
Later, our team of analysts takes it further with manual verification, using proprietary tools for data cleaning and validation to ensure accuracy and reliability. We cross-check and enhance our findings through press and media monitoring, integrating information from trusted news outlets and venture capital aggregators. Finally, we stay ahead of the curve by monitoring social networks like LinkedIn and X.com.